News

Atavistik Bio Welcomes Dr. Susan Pandya as New CMO

Atavistik Bio Welcomes Dr. Susan Pandya as New CMO

Atavistik Bio's New Strategic Appointment

Atavistik Bio is entering an exciting era with the appointment of Dr. Susan Pandya, M.D., as Chief Medical Officer. With an impressive two-decade career in drug development, her expertise in precision medicine, particularly in oncology and hematology, positions her as a vital asset for the company's future initiatives.

Dr. Pandya's Expertise in Drug Development

Dr. Pandya has held senior leadership roles at notable companies like Servier Pharmaceuticals and Agios Pharmaceuticals. Her extensive background includes guiding oncology programs through various phases of clinical development, showcasing her capability in steering innovative medical solutions through challenging landscapes.

Contributions to Clinical Trials

Following her appointment, Dr. Pandya will oversee the ongoing Phase 1 clinical trial for ATV-1601, an allosteric selective inhibitor specifically designed for treating AKT1 E17K-driven solid tumors. This role is pivotal as Atavistik Bio aims to navigate the complexities of bringing new therapeutic options to market.

Influence on Preclinical Programs

Beyond clinical trials, Dr. Pandya will significantly impact Atavistik Bio's preclinical pipeline. Her leadership will help streamline programs aimed at advancing from research to clinical application, ensuring that the development process remains efficient and targeted.

CEO's Vision for Atavistik Bio

"We are very excited to welcome Susan to the Atavistik Bio team as we transition to a clinical stage organization," commented Bryan Stuart, the CEO. He emphasized the importance of Dr. Pandya's background and expertise in successfully guiding clinical studies through regulatory approvals, a key component in advancing the company's mission.

Significance in Precision Oncology

Dr. Pandya articulated her enthusiasm, stating, "Atavistik Bio's commitment to discovering and developing both best-in-class and first-in-class allosteric therapeutics for significantly underserved patient populations represents an important advancement in the field of precision oncology medicine." Her passion aligns perfectly with the company's goals as they work to address the critical needs of patients in dire situations.

Dr. Pandya’s Professional Background

Before joining Atavistik Bio, Dr. Pandya served as Vice President of Clinical Development and was the Global Head of late-stage oncology at Servier Pharmaceuticals. In this role, she managed extensive clinical development programs, contributing to the corporate strategy regarding oncology and hematology advancements.

Her Academic and Leadership Credentials

Dr. Pandya's academic credentials include earning her M.D. from Tufts University School of Medicine, followed by completing her residency in internal medicine and fellowship in hematology/oncology. She has also been part of the Board of Directors of MOMA Therapeutics, enhancing her influence in the biotechnology sector.

About Atavistik Bio

Atavistik Bio is at the forefront of developing transformative precision allosteric therapeutics aimed at addressing significant unmet medical needs. Since its founding, the company has built a robust pipeline of therapeutics that hold promise for greater efficacy and tolerability, leveraging the power of allosteric mechanisms.

An Emerging Leader in Biotechnology

The company is currently conducting a Phase 1 clinical trial of ATV-1601, showcasing their commitment to innovative research and development in the oncology space. Supported by experienced drug hunters and recognized investors, Atavistik Bio is poised for substantial growth in its therapeutic offerings.

Frequently Asked Questions

Who is Dr. Susan Pandya?

Dr. Susan Pandya is the new Chief Medical Officer at Atavistik Bio, bringing 20 years of experience in drug development in oncology and hematology.

What will Dr. Pandya's role involve?

Dr. Pandya will lead clinical strategy and execution for the company's trials, particularly focusing on the ongoing Phase 1 trial for ATV-1601.

What is ATV-1601?

ATV-1601 is an allosteric selective inhibitor targeting AKT1 E17K-driven solid tumors, and it is currently being evaluated in a clinical trial.

How does Atavistik Bio view patient needs?

The company is dedicated to solving unmet patient needs by developing novel allosteric therapeutics for underserved populations in the oncology field.

Where can I learn more about Atavistik Bio?

You can learn more by visiting Atavistik Bio's official website and following them on social media platforms such as LinkedIn.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading